Literature DB >> 729623

Activity and duration of action of pindolol and alprenolol compared in healthy volunteers.

W H Aellig.   

Abstract

An improvement in the prognosis of myocardial infarction has been reported after long term treatment with alprenolol 200 mg twice daily. Therefore, an experiment was carried out to find the dose of pindolol given once daily which would show cardiac beta-adrenoceptor blockade at least equipotent to that obtained during treatment with alprenolol 200 mg twice daily. Cardiac beta-adrenoceptor blocking activity and its time course during treatment with pindolol (15 mg and 20 mg given once daily) and alprenolol (200 mg given 12-hourly) for three days were compared in 6 healthy volunteers. The reduction in exercise-induced tachycardia as a measure of cariac beta-adrenoceptor blockade was significantly greater after pindolol 15 mg and 20 mg than after alprenolol 200 mg. On the morning of the fourth day, i.e. 24 h after the last dose of pindolol and only 12 h after the last dose of alprenolol, the effects of pindolol at both dose levels were slightly greater than those of alprenolol. This difference was not statistically significant. It can be concluded that pindolol 15 mg once daily produces a cardiac beta-adrenoceptor blockade at least equipotent to that of alprenolol 200 mg given 12-hourly.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 729623     DOI: 10.1007/bf00611898

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Plasma catechol amine concentrations in myocardial infarction and angina pectoris.

Authors:  P C GAZES; J A RICHARDSON; E F WOODS
Journal:  Circulation       Date:  1959-05       Impact factor: 29.690

2.  Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. A multicentre international study.

Authors: 
Journal:  Br Med J       Date:  1975-09-27

3.  Protective effect of beta adrenoceptor blockade in experimental coronary occlusion in conscious dogs.

Authors:  M I Khan; J T Hamilton; G W Manning
Journal:  Am J Cardiol       Date:  1972-12       Impact factor: 2.778

4.  Free noradrenaline and adrenaline excretion in relation to the development of cardiac arrhythmias and heart-failure in patients with acute myocardial infarction.

Authors:  D E Jewitt; D Reid; M Thomas; C J Mercer; C Valori; J P Shillingford
Journal:  Lancet       Date:  1969-03-29       Impact factor: 79.321

5.  Letter: Hypertension and myocardial infarction.

Authors:  D M Lambert
Journal:  Br Med J       Date:  1974-09-14

6.  Long-term beta blockade: possible protection from myocardial infarction.

Authors:  K M Fox; M P Chopra; R W Portal; C P Aber
Journal:  Br Med J       Date:  1975-01-18

7.  beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

8.  Autonomic disturbance at onset of acute myocardial infarction.

Authors:  S W Webb; A A Adgey; J F Pantridge
Journal:  Br Med J       Date:  1972-07-08

9.  Drug defaulting in a general practice.

Authors:  A M Porter
Journal:  Br Med J       Date:  1969-01-25

10.  Long-term treatment with beta-blockers after myocardial infarction.

Authors:  G Ahlmark; H Saetre
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

View more
  3 in total

Review 1.  Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  D W Harron; K L Goa; H D Langtry
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

Review 2.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

3.  Concentration-effect and time-effect relationships of carteolol.

Authors:  T Ishizaki; A Ohnishi; T Sasaki; K Chiba; T Suganuma; K Kushida
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.